Page History

Sophie Vandebroek is Xerox's chief technology officer and president of the Xerox Innovation Group, responsible for overseeing Xerox's research centers in Europe, Asia, Canada and US as well as the Palo Alto Research Center. Previously, Vandebroek was chief engineer of Xerox Corporation and vice president of the Xerox Engineering Center, technical advisor to Xerox's chief operating officer, and director of the Xerox Research Centre of Canada. She is a fellow of the Institute of Electrical and Electronics Engineers and the Belgian-American Educational Foundation, as well as a Fulbright Fellow. She holds 12 US patents. Vandebroek is a member of the board of directors of Analogic Corporation and Nypro Corporation and is a member of the US National Academies Committee on Science, Technology and Law. She is a trustee of Worcester Polytechnic Institute and serves on the engineering advisory council at MIT.

Todd C. Zion founded SmartCells, Inc. in 2003 to develop SmartInsulin™,
the first glucose-regulated, injectable formulation for treating diabetes.
As SmartCells' president and CEO, He was instrumental in raising $10
million in equity financing from individual investors and $10 million in
grants to support research and clinical development. In December 2010,
Merck and Co. acquired SmartCells for over $500 million in cash and
clinical milestone payments. He developed the SmartInsulin™ technology
as part of his doctoral thesis work at MIT. Prior to enrolling at MIT,
he worked as a polymer development engineer at Eastman Kodak. He
now enjoys advising technology entrepreneurs through MIT's Venture
Mentoring Service. He also serves on a number of advisory boards including
those of the Beth Israel Deaconess Medical Center and the CNY
Biotech Accelerator.

72 Nanepashemet St.
Marblehead, MA 01945
857 389-2273
todd@toddzion800 Phillips Road
Mail Stop 105-48C
Webster, NY 14580-9720
585 422-9449
sophie.vandebroek@xerox.com